Jump to content

Publication: The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial

From CAMIH
Revision as of 09:21, 28 August 2024 by Lbordihn (talk | contribs) (Created page with "{{Publication |Title=The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial |Topic=Ginger (also contains zerumbone) |Author=Marx, W; McCarthy, A; Ried, K; McKavanagh, D; Viletta, L; Sali, A; Lohning, A; Isenring, E |Year=2017 |Journal=Nutrients 2017 |DOI=https://doi.org/10.3390/nu9080867 |Authors Abstract=Gi...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


Reference
Title The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial
Topic Ginger (also contains zerumbone)"Ginger (also contains zerumbone)" is not in the list (Aloe vera, Cannabinoids, Curcumin, Enzymes (bromelain papain), Folic acid, Ginkgo, Green tea (EGCG), Low-carbohydrate or ketogenic diet, Lycopene, Selenium, ...) of allowed values for the "Topic" property.
Author Marx, W, McCarthy, A, Ried, K, McKavanagh, D, Viletta, L, Sali, A, Lohning, A, Isenring, E
Year 2017
Journal Nutrients 2017
DOI https://doi.org/10.3390/nu9080867

Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.

Ginger supplementation could be an effective adjuvant treatment for chemotherapy-induced nausea (CIN). The aim of this clinical trial was to address significant methodological limitations in previous trials. Patients (N = 51) were randomly allocated to receive either 1.2 g of standardised ginger extract or placebo per day, in addition to standard anti-emetic therapy, during the first three cycles of chemotherapy. The primary outcome was CIN-related quality of life (QoL) measured with the Functional Living Index- Emesis (FLIE) questionnaire. Secondary outcomes included acute and delayed nausea, vomiting, and retching as well as cancer-related fatigue, nutritional status, and CIN and vomiting-specific prognostic factors. Over three consecutive chemotherapy cycles, nausea was more prevalent than vomiting (47% vs. 12%). In chemotherapy Cycle 1, intervention participants reported significantly better QoL related to CIN (p = 0.029), chemotherapy-induced nausea and vomiting (CINV)-related QoL (p = 0.043), global QoL (p = 0.015) and less fatigue (p = 0.006) than placebo participants. There were no significant results in Cycle 2. In Cycle 3, global QoL (p = 0.040) and fatigue (p = 0.013) were significantly better in the intervention group compared to placebo. This trial suggests adjuvant ginger supplementation is associated with better chemotherapy-induced nausea-related quality of life and less cancer-related fatigue, with no difference in adverse effects compared to placebo.



This publication is referenced in the following studies:

  1. Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial